Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International Experience

Non-Malignant Blood Disorders

Real-World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry

Am J Hematol

Röth A, Patriquin CJ, Szer J, Terriou L, Patel AS, Metzger J, Gustovic P, Nishimura JI, Brodsky RA

doi: 10.1002/ajh.70268

EHA 2025

Lymphoma

Real-world effectiveness and safety of second-line axi-cel in patients with R/R LBCL

Non-Malignant Blood Disorders

Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study

Br J Haematol

Lucchini E, Vianelli N, Consoli U, Carli G, Carrai V, Carpenedo M, De Stefano V, Gaidano G, Palandri F, Auteri G, Rossi E, Patriarca A, Innao V, Marchesini G, Ballerini M, Rossetti MC, Mosini G, Sciancalepore P, Agnelli Giacchello J, Musto P, Rivolti E, Soverini G, Borchiellini A, Clissa C, Pane F, Galimberti S, Pavone V, Poloni A, Buccisano F, Musso M, Fazi P, Paoloni F, Gorreo Renzulli L, Zaja F

doi: 10.1111/bjh.70069

Skin Cancer

Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study

Int J Cancer

Gutzmer R, Weichenthal M, Eigentler T, Mohr P, Sickmann T, Dücker P, Gebhardt C, Haferkamp S, Kähler KC, Meier F, Pföhler C, Sindrilaru A, Terheyden P, von Wasielewski I, Ugurel S, Ulrich J, Utikal J, Weishaupt C, Schadendorf D

doi: 10.1002/ijc.70440

Sarcoma

Trabectedin in the treatment of soft tissue sarcoma: Real-world data on effectiveness, safety, and financial implications from a European comprehensive cancer center

Int J Cancer

Giraud JS, Watson S, Acramel A, Laurence V, Tzanis D, Bonvalot S, El Zein S, Nicolas N, Cros C, Desmaris R, Bonnet C

doi: 10.1002/ijc.70403

Leukemia

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse

Am J Hematol

Tsirigotis P, Garofalaki M, Lazana I, Liga M, Gigantes S, Kopsaftopoulou A, Tziotziou E, Roumelioti A, Tsintziloni E, Hatzis S, Konstantellos I, Benetatos L, Barbarousi D, Tzenou T, Asimakopoulos JV, Karagiannidi A, Barakos G, Delimpasi S, Stoumbos D, Stamouli M, Plata E, Valera K, Giannouli S, Chatzidimitriou C, Gkolfinopoulou G, Siakantaris MP, Kotsopoulou M, Voulgarelis M, Chondropoulos S, Zina V, Gkirkas K, Kapsali E, Matsouka C, Vassilakopoulos TP, Spyridonidis A, Angelopoulou M, Baltadakis I

doi: 10.1002/ajh.70322

CHICAGO 2025

Breast Cancer

T-DXd rechallenge after grade 1 interstitial lung disease appears safe and clinically beneficial in a real-world setting

SABCS 2025

Breast Cancer

Sacituzumab govitecan shows clinically meaningful activity in real-world patients with metastatic TNBC and intracranial disease

Genitourinary Cancer

Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study

Prostate Cancer Prostatic Dis

Büttner T, Rizzo M, Bernal Vaca L, Molina-Cerrillo J, Alonso-Gordoa T, Juárez A, Buchler T, Seront E, Kucharz J, Gandur Quiroga MN, Bourlon MT, Bögemann M, Kopecky J, Rescigno P, Fiala O, Rodriguez-Vida A, Myint ZW, Ürün Y, Scagliarini S, Poprach A, Matthews D, Li H, Rizzo A, Mosca A, Lenci E, Melichar B, Wenzel M, Mandell P, Massari F, Antonarakis ES, Santoni M

doi: 10.1038/s41391-025-01067-3

Related content